Antibody Drug Conjugates (ADCs) represent one of the most complex and successful classes of drugs currently under development. The aim of an ADC is to improve the therapeutic index by combining the targeting properties of an antibody with a highly cytotoxicity payload that is attached via an appropriate linker. The linker represents a critical element of the overall ADC design. Composed of different structural elements, the linker in conjunction with the other ADC components undergoes developability assessment to evaluate functionality, safety and manufacturability to ensure ADC design is aligned with the ideal Target Product Profile (TPP). Data generated through developability can inform potential liabilities and offer the opportunity to adjust the design of the ADC prior to development. This webinar will describe the many varied and different approaches that have been applied to linker design and its subsequent impact on ADC properties, and ultimately how optimal linker design drives the success of ADC programs. The webinar will also incorporate previous ADC webinar series topics including oligonucleotide design and development, ADC to GMP requirements and overall application of developability for ADC lead candidate selection.
Key Learning Objectives
- Linkers – What are they, why are they important and why do we need to consider them?
- Fundamentals of linker design to drive successful ADC programs
- Case studies of linker development
- What will drive the next generation of linker technology entering the clinic – ‘the decade of ADCs’
Target audience
- Pharmaceutical companies
- Small biotech (SMEs)
- Biopharmaceutical Consultants
- Conjugation chemists
- Scientists & Project Leaders
- CMC Management & Operations
- Directors
- Preclinical Development
- Directors
- Biotherapeutics
- C-levels; CSO
- COO
- CEO
- Head of
- Scientific leaders
- Synthetic chemists
